Journal: Cancer science
This retrospective real-world study evaluated the efficacy and safety of third-generation EGFR-TKIs combined with platinum-based chemotherapy as first-line treatment in 382 patients with advanced EGFR-mutant non-small cell lung cancer.
The results showed:
- Median progression-free survival: 30.9 months
- Median overall survival: 53.9 months
- Objective response rate: 76.4%
- Disease control rate: 98.2%
- Grade 3 or higher adverse events: occurred in 35.9% of patients
No significant differences were observed among the osimertinib, aumolertinib, and furmonertinib groups in terms of progression-free survival or severe toxicity.
Overall, combining third-generation EGFR-TKIs with pemetrexed-based chemotherapy demonstrated favorable efficacy and manageable safety, supporting this approach as a viable first-line strategy in advanced EGFR-mutant NSCLC.